United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy?

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with United Therapeutics (UTHR) currently holding a Momentum Style Score of B [2] - Style Scores complement the Zacks Rank system, which has a strong track record of outperforming the market, with UTHR rated as 1 (Strong Buy) [3] Group 2: Performance Metrics of United Therapeutics - UTHR shares have increased by 2.75% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 1.76% [5] - Over the last quarter, UTHR shares have risen by 23.21%, and over the past year, they have gained 41.37%, compared to the S&P 500's increases of 8.91% and 20.56% respectively [6] - The average 20-day trading volume for UTHR is 480,853 shares, indicating a bullish sign if the stock is rising with above-average volume [7] Group 3: Earnings Outlook - In the past two months, 5 earnings estimates for UTHR have been revised upwards, raising the consensus estimate from $24.48 to $25.59 [9] - For the next fiscal year, 7 estimates have also moved higher, with no downward revisions during the same period [9] - These positive trends contribute to UTHR's status as a 1 (Strong Buy) stock with a Momentum Score of B, making it a potential pick for near-term gains [9]